Cefaclor

CHEMBL1201018 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
367.8 g/mol
LogP
-1.8
Phase
4

A second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to bacterial cell death. It is effective against a range of gram-positive and gram-negative bacteria and is used for respiratory, skin, and urinary tract infections. As with other cephalosporins, it should be used with caution in patients with penicillin allergy due to possible cross-reactivity.

Molecular Weight

367.8000 g/mol

LogP

-1.80

TPSA

138.00 Ų

Lipinski RO5

Pass

Mechanism of Action

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1.O

InChI

InChI=1S/C15H14ClN3O4S.H2O/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7;/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23);1H2/t9-,10-,14-;/m1./s1

Molecular Formula

C15H14ClN3O4S

HBD / HBA

3 / 6

Rotatable Bonds

4

Heavy Atoms

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to bacterial cell death. It is effective against a range of gram-positive and gram-negative bacteria and is used for respiratory, skin, and urinary tract infections. As with other cephalosporins, it should be used with caution in patients with penicillin allergy due to possible cross-reactivity.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefaclor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201018. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 51039. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.